Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Next Previous
Trial Profile

Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radgocitabine (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Delta-Fly Pharma

Most Recent Events

  • 28 Feb 2025 According to Delta-Fly Pharma media release, company is moving to the Phase II portion of the trial for efficacy testing as of today, on 28th Feb., 2025.
  • 09 Dec 2024 According to Delta-Fly Pharma media release, the data review committee (DMC) has approved the tolerability of the first three patients enrolled in this trial conducted at five US clinical sites for patients with acute myeloid leukemia (AML). Three more patients will be added at the current dosage regimen, and after confirmation of the tolerability, the study will move to Phase II.
  • 10 Sep 2024 According to Delta-Fly Pharma media release, company announced first patient was enrolled at the University of Virginia Hospital based on the approval of the Investigational Review Board (IRB).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top